Health Economics Model Shows Cervarix(R) Cross-Protective Efficacy Could Provide Greater Cost Reductions Than Protection Against Genital Warts

October 13, 2009 by admin 

Results from a modelling study have showed that cross-protective efficacy of GlaxoSmithKline’s Cervarix┬« against cervical cancer-causing human papillomavirus (HPV) types1,2 could provide greater public health cost reductions than the cost reductions potentially offered by Gardasil┬« due to its efficacy against Genital Warts.

Source: Health Economics Model Shows Cervarix(R) Cross-Protective Efficacy Could Provide Greater Cost Reductions Than Protection Against Genital Warts

Comments

Feel free to leave a comment...
and oh, if you want a pic to show with your comment, go get a gravatar!





Security Code: